Additional information for CF care teams, pharma colleagues, researchers and research funders.
CF Care Teams
Are you frustrated by the lack of effective treatments for gut symptoms in your CF patients?
Do you think we need a better understanding of gut symptoms in CF?
If the answer is “yes” then the GRAMPUS-CF Strategic Research Centre can help you help your patients.
What do we want to figure out?
Which symptoms are most troublesome to people with CF?
Do symptoms “cluster” together in a different way affected individuals?
Are different treatments needed for different “clusters”?
We will test these treatments in future trials - these may be new or repurposed drugs, dietary changes or something else entirely.
What can you do to help?
Encourage people with CF attending your CF Centre to take part in GRAMPUS-CF.
What will my patients need to do?
We are inviting people with CF to complete gut symptom questionnaires on 3 occasions 6 months apart.
They can do this by downloading an app that will guide them through the questionnaires.
Participants in Nottingham or Leeds can complete the questionnaires at a face to face visit.
One hundred participants (mostly from Nottingham and Leeds) can also provide blood or stool (“poo”) samples for the inflammation and microbiome studies.
Another 40 participants (mostly from Nottingham and Leeds) can take part in the MRI studies.
The MRI studies involve a one day visit to the Sir Peter Mansfield Imaging Centre at the University of Nottingham.
Thank you for your help. Together we can bring an end to gut misery in CF!
Pharma colleagues, researchers and research funders
Interested in collaborating with the GRAMPUS-CF Strategic Research Centre?
Contact us at grampuscf@nottingham.ac.uk
Read our published work
Calthorpe R, Goodchild N, Gleetus V, Premakumar V, Hayee B, Elliott Z, Evans B, Rowbotham N, Carr S, Barr H, Horsley A, Peckham D, Smyth A. A grumbling concern: an international survey of gastrointestinal symptoms in cystic fibrosis in the modulator era [version 1; peer review: awaiting peer review]. NIHR Open Research. 2023;3.18. https://doi.org/10.3310/nihropenres.13384.1
Rowbotham NJ, Smith S, Elliott ZC, Cupid B, Allen LJ, Cowan K, Allen L, Smyth AR. A refresh of the top 10 research priorities in cystic fibrosis. Thorax. 2023;78:840-3 http://dx.doi.org/10.1136/thorax-2023-220100
Marsh R, Gavillet H, Hanson L, Ng C, Mitchell-Whyte M, Major G, Smyth AR, Rivett D, van der Gast C. Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis. J Cyst Fibros. 2022;21:506-13 https://doi.org/10.1016/j.jcf.2021.11.014
Dellschaft NS, Ng C, Hoad C, Marciani L, Spiller R, Stewart I, Menys A, Barr H, Gowland PA, Major G, Smyth AR. Magnetic resonance imaging of the gastrointestinal tract shows reduced small bowel motility and altered chyme in cystic fibrosis compared to controls. J Cyst Fibros. 2022;21:502-5. https://doi.org/10.1016/j.jcf.2021.12.007
Ng C, Dellschaft NS, Hoad CL, Marciani L, Ban L, Prayle AP, Barr HL, Jaudszus A, Mainz JG, Spiller RC, Gowland P, Major G, Smyth AR. Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by Magnetic Resonance Imaging. J Cyst Fibros. 2021;20:591-7 https://doi.org/10.1016/j.jcf.2020.06.004
Smith S, Rowbotham N, Davies G, Gathercole K, Collins SJ, Elliott Z, Herbert S, Allen L, Ng C, Smyth A. How can we relieve gastrointestinal symptoms in people with cystic fibrosis? An international qualitative survey. BMJ Open Respir Res. 2020;7:e000614. http://dx.doi.org/10.1136/bmjresp-2020-000614
Rowbotham NJ, Smith S, Leighton PA, Rayner OC, Gathercole K, Elliott ZC, Nash EF, Daniels T, Duff AJA, Collins S, Chandran S, Peaple U, Hurley MN, Brownlee K, Smyth AR. The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers. Thorax 2018; 73(4): 388-90. http://dx.doi.org/10.1136/thoraxjnl-2017-210473